The Biggest Challenge in Treating Alzheimer Disease: A Conversation With Oleg Tcheremissine, MD

Psychiatric Times recently sat down with Oleg V. Tcheremissine, MD, who has more than 20 years of clinical and research experience in neuropsychiatric drug development, to discuss the evolving Alzheimer disease treatment landscape and the opportunities emerging from recent scientific advances.

When asked what he considers the biggest challenge in Alzheimer disease today, Tcheremissine pointed to the disorder's inherent complexity. Although amyloid plaque has become a major therapeutic target and has driven many of the field's most significant recent advances, he emphasized that Alzheimer disease is far more than a single-pathway illness. Rather, it is a multifactorial neurodegenerative disease involving numerous biological processes that are still being unraveled.

One of the most important developments, according to Tcheremissine, has been the rapid evolution of imaging technologies and biomarker science. These advances now allow investigators to evaluate amyloid plaque not only quantitatively but also qualitatively, providing unprecedented insight into whether investigational therapies are successfully reaching and engaging their intended targets.

"Our advancement in imaging techniques and biomarkers really allowed us to not only quantitatively but qualitatively measure plaque. As someone who has been working in psychiatric drug development for decades, it was very, very interesting to actually see how the pharmacological agents or compounds in development engage the target. It is the first time in my life as a drug developer and investigator that I can actually see how drug engages with our target," Tcheremissine said.

He noted that these technological advances are helping reshape the drug development process by giving researchers greater confidence in evaluating treatment effects earlier in development and refining therapeutic strategies.

Beyond amyloid-directed therapies, Tcheremissine also highlighted a broader shift occurring across the Alzheimer disease pipeline. Researchers are increasingly investigating therapies that target other aspects of disease biology, including tau pathology and neuroinflammation. The expansion of these pharmacologic approaches reflects a growing recognition that successfully treating Alzheimer disease will likely require addressing multiple disease mechanisms rather than focusing on amyloid alone.

Dr Tcheremissine is a professor and research director in the Department of Psychiatry and Behavioral Medicine at Atrium Health/Wake Forest Medical University-Charlotte Campus.